Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GSTP1 | P09211 | 7/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24922866 | 0.93 | SIRT2 (0.47) | NOTUMSIRT2MAPTTSHRGSTP1 | |
| SCHEMBL24922905 | 0.80 | SIRT2 (0.39) | SIRT2MAPTTSHRGSTP1LMNA | |
| SCHEMBL24922897 | 0.78 | SIRT2 (0.42) | NOTUMSIRT2MAPTTSHRGSTP1 | |
| SCHEMBL24922864 | 0.78 | NOTUM (0.63) | NOTUMSIRT2TSHRNPC1MAPK1 | |
| SCHEMBL8897496 | 0.77 | HSD17B10 (0.51) | NOTUMSIRT2MAPTTSHRGSTP1 | |
| SCHEMBL5351217 | 0.76 | SIRT2 (0.73) | NOTUMSIRT2MAPTTSHRGSTP1 | |
| SCHEMBL8892261 | 0.75 | LMNA (0.64) | SIRT2MAPTTSHRLMNAATM | |
| SCHEMBL8899624 | 0.74 | MAPT (0.64) | MAPTTSHRLMNAATMFFAR1 | |
| SCHEMBL8889364 | 0.74 | NPC1 (0.62) | MAPTTSHRLMNANPC1MAPK1 | |
| SCHEMBL13860745 | 0.72 | SIRT2 (0.51) | NOTUMSIRT2MAPTTSHRGSTP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11566009-B1 | Energetic compound embodiments and methods of making and using the same | TRIAD NATIONAL SECURITY, LLC (US) | 2023-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566009-B1 | Energetic compound embodiments and methods of making and using the same | EWSR1, PARP6, PARP4 | NOTUM 1412/4885SIRT2 1298/4885MAPT 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.